Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy.
A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Posaconazole or alternative fungal treatment | Drug | Dosage of Posaconazole: Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety: adverse events | Depending on treatment modality every 2 to 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors Performance status | Depending on treatment modality every 2 to 4 weeks | |
| Treatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
Not provided
| ID | Term |
|---|---|
| D009181 | Mycoses |
| ID | Term |
|---|---|
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C101425 | posaconazole |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Depending on treatment modality every 2 to 4 weeks |
| Adverse events; Survival status | Depending on treatment modality every 2 to 4 weeks |